Wunderlich Capital Managemnt lowered its holdings in Shire PLC (NASDAQ:SHPG) by 1.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 8,314 shares of the biopharmaceutical company’s stock after selling 97 shares during the quarter. Wunderlich Capital Managemnt’s holdings in Shire PLC were worth $1,374,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Inspirion Wealth Advisors LLC lifted its holdings in Shire PLC by 0.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 8 shares during the period. Synovus Financial Corp lifted its holdings in Shire PLC by 0.4% in the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 11 shares during the period. Level Four Advisory Services LLC lifted its holdings in Shire PLC by 0.5% in the 1st quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 13 shares during the period. Baldwin Investment Management LLC lifted its holdings in Shire PLC by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 23 shares during the period. Finally, Hartford Financial Management Inc. lifted its holdings in Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 19.28% of the company’s stock.
Shire PLC (NASDAQ:SHPG) traded up 0.23% on Thursday, reaching $152.35. The company had a trading volume of 345,709 shares. Shire PLC has a 52 week low of $139.36 and a 52 week high of $194.60. The stock’s 50-day moving average is $152.94 and its 200-day moving average is $165.41. The company has a market capitalization of $45.38 billion, a P/E ratio of 68.17 and a beta of 1.63.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities research analysts forecast that Shire PLC will post $14.93 EPS for the current fiscal year.
The business also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.1527 per share. The ex-dividend date is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio is currently 41.07%.
COPYRIGHT VIOLATION NOTICE: This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/10/12/shire-plc-shpg-shares-sold-by-wunderlich-capital-managemnt.html.
SHPG has been the subject of several research analyst reports. Piper Jaffray Companies set a $159.00 price objective on Shire PLC and gave the stock a “hold” rating in a report on Wednesday, July 26th. ValuEngine cut Shire PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research cut Shire PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub cut Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Royal Bank Of Canada set a $213.00 target price on Shire PLC and gave the company a “buy” rating in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $220.91.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.